Considering the growing demography and the aging of the population, cancer remains one of the main causes of mortality.


In 2018, there were approximately 18.1 million new cancer cases worldwide, and this number is expected to reach 29.5 million by 2040. Same year, 9.5 million people died as a result of cancer. In Switzerland, the number of new cancer cases was 56,506 in 2018, affecting around 0.7% of the population, and 18,377 people died as a result of the disease (Source: Globocan 2018).


Our association was born from the interest of our members in supporting and developing innovative methods of diagnostic and treatment of cancer. Three of our members are recognised researchers, who are developing a promising method for diagnosing cancer and other pathologies. Other members joined the association to learn and share information about different approaches to treat cancer.


  • Our independent scientific project brings together three researchers, who have developed an efficient diagnostic algorithm using data from published and accessible studies. This Machine Learning method is based on innovative approaches to gene expression analysis. It can already predict the success of treatment for breast cancer and multiple myeloma with exceptional accuracy.


  • We aim to create a portal for innovative methods of cancer treatment and ongoing clinical trials in order to make information available to the public and patients, in particular, to the French-speaking community. With our scientific team’s vast expertise in advanced biomedical research and technologies, we will provide information on new therapies and clinical trials in accessible terms. This will help people 1) be informed about new treatments that are not always available in their home country, and 2) access clinical trials, which use promising therapies.